Joaquin Espinosa
Linda Crnic Institute for Down Syndrome, CU Anschutz · Linda Crnic Institute for Down Syndrome · University of Colorado, Denver
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joaquin Espinosa as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:23 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07598643 · Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1University of Colorado, Denver · recruiting · Down Syndrome · principal investigator
- Ph2NCT05662228 · Therapies for Down Syndrome Regression DisorderUniversity of Colorado, Denver · completed · Down Syndrome, Regression · principal investigator
- Ph2/Ph3NCT04348071 · Safety and Efficacy of Ruxolitinib for COVID-19University of Colorado, Denver · withdrawn · COVID-19 · principal investigator
- Ph2/Ph3NCT04340232 · Safety and Efficacy of Baricitinib for COVID-19University of Colorado, Denver · withdrawn · COVID-19 · principal investigator
- Ph2NCT04246372 · Tofacitinib for Immune Skin Conditions in Down SyndromeUniversity of Colorado, Denver · completed · Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema · principal investigator
- N/ANCT02864108 · The Human Trisome ProjectUniversity of Colorado, Denver · recruiting · Down Syndrome, Trisomy 21 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Data Science for Developing Scholars in Down Syndrome Research (DS3)R25HD114950 · NICHD · UNIVERSITY OF COLORADO DENVER · fiscal years 2024 to 2026 · $392,503 awarded in 2026Same name and institution; not confirmed by an ID
- Down Syndrome Connect RegistryOT2HD117033 · NICHD · UNIVERSITY OF COLORADO DENVER · fiscal years 2024 to 2026 · $1,298,881 awarded in 2026Same name and institution; not confirmed by an ID
- Human Trisome Project - Latin America NetworkU01HD116469 · NICHD · UNIVERSITY OF COLORADO DENVER · fiscal years 2024 to 2026 · $269,406 awarded in 2026Same name and institution; not confirmed by an ID
- Mechanistic investigation of therapies for Down Syndrome Regression DisorderR33HD109748 · NICHD · UNIVERSITY OF COLORADO DENVER · fiscal years 2024 to 2026 · $1,297,326 awarded in 2026Same name and institution; not confirmed by an ID
- Multidimensional investigation of auditory dysfunction in Down syndromeR01DC021819 · NIDCD · UNIVERSITY OF COLORADO DENVER · fiscal years 2024 to 2026 · $1,014,909 awarded in 2026Same name and institution; not confirmed by an ID
- Risk for Severe/Profound Intellectual Disability in Down SyndromeR01HD113720 · NICHD · COLORADO STATE UNIVERSITY · fiscal years 2024 to 2026 · $677,780 awarded in 2026Same name and institution; not confirmed by an ID
- The INCLUDE Project Down Syndrome Biorepository (DS-Biorepository)U24AG092191 · NIA · UNIVERSITY OF COLORADO DENVER · fiscal years 2024 to 2026 · $5,325,989 awarded in 2026Same name and institution; not confirmed by an ID
- Trisomy 21 Model AtlasR24OD035579 · OD · UNIVERSITY OF COLORADO DENVER · fiscal years 2023 to 2026 · $737,886 awarded in 2026Same name and institution; not confirmed by an ID
- Admin supplement - Autism in young children with Down SyndromeR01HD110542 · NICHD · COLORADO STATE UNIVERSITY · fiscal years 2024 · $423,143 awarded in 2024Same name and institution; not confirmed by an ID
- JAK Inhibition in Down SyndromeR33AR077495 · NIAMS · UNIVERSITY OF COLORADO DENVER · fiscal years 2022 to 2024 · $907,994 awarded in 2024Grant number is on one of their registry trials
- Mechanistic investigation of therapies for Down Syndrome Regression DisorderR61HD109748 · NICHD · UNIVERSITY OF COLORADO DENVER · fiscal years 2022 to 2023 · $1,176,407 awarded in 2023Same name and institution; not confirmed by an ID
- Mechanisms of gene expression control in the p53 networkR01CA117907 · NCI · UNIVERSITY OF COLORADO DENVER · fiscal years 2006 to 2022 · $325,734 awarded in 2022Same name and institution; not confirmed by an ID
- JAK Inhibition in Down SyndromeR61AR077495 · NIAMS · UNIVERSITY OF COLORADO DENVER · fiscal years 2019 to 2021 · $612,030 awarded in 2021Same name and institution; not confirmed by an ID
- Interferon hyperactivity, COVID19, and Down syndromeR01AI150305 · NIAID · UNIVERSITY OF COLORADO DENVER · fiscal years 2019 to 2020 · $619,607 awarded in 2020Same name and institution; not confirmed by an ID
- Mechanisms of gene expression control during the cellular response to hypoxiaR01GM120109 · NIGMS · UNIVERSITY OF COLORADO DENVER · fiscal years 2016 to 2019 · $307,113 awarded in 2019Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI RONALD J. SOKOL · fiscal years 2013 to 2017Named on NCT02864108
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:23 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- 135 citationsRCR 13.6
- Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome.Cell Rep · 2019119 citationsRCR 4.6
- Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial.Radiother Oncol · 201670 citationsRCR 3.3
- Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain.J Pain Symptom Manage · 201167 citationsRCR 3.0
- A comparative trial of two modalities of speech intervention for compensatory articulation in cleft palate children, phonologic approach versus articulatory approach.Int J Pediatr Otorhinolaryngol · 199964 citationsRCR 4.4
- 62 citationsRCR 2.2
- A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies.Cancer Chemother Pharmacol · 201555 citationsRCR 2.1
- 40 citationsRCR 6.8
- Does fluid hysteroscopy increase the stage or worsen the prognosis in patients with endometrial cancer? A randomized controlled trial.Eur J Obstet Gynecol Reprod Biol · 200439 citationsRCR 0.9
- Whole-body vibration training effects on the physical performance of basketball players.J Strength Cond Res · 201036 citationsRCR 2.0